展覽1.1

科創板時尚文化控股有限公司

承銷協議

紐約州紐約市

2024年10月10日

凱泰證券有限公司，作爲多家承銷商的代表

40 Wall Street, Suite 3600

紐約市，NY 10005

尊敬的女士們，先生們：

Star Fashion Culture Holdings Limited，一家英屬維爾京群島公司（與其附屬公司及關聯公司統稱爲其子公司和附屬公司，包括但不限於註冊聲明中披露或描述的所有實體，作爲Star Fashion Culture Holdings Limited的子公司或附屬公司 （以下簡稱“公司”）在此確認與WestPark Capital，Inc.（以下簡稱「你」（包括其相關公司）或“協議”）與Cathay Securities，Inc.（以下簡稱「您」（包括其相應部分）或“代表人發行文件中命名的承銷商達成協議 附件1 代表正在充當代表的前提下（代表和其他承銷商合稱“承壓商「股份」或單獨稱爲「穩定的股份」票據的購買金額如下：

1. 股份的購買和銷售.

1.1 公司 股份.

1.1.1 大自然 和公司股份的購買.

(i)根據本文件中包含的陳述和保證，但受本文件所載條款和條件約束，公司同意向承銷商發行並賣出2,150,000股公司已授權但未發行的A類普通股，每股面值0.00001美元（“普通股”。公司賣給承銷商的普通股統稱爲“實股本文所述。

(ii) 公司股票將以每股公開發售價格對待，該價格列於附表中，並作爲本文件的一部分。 附表2-A 若干購買價格”). 各獨立的承銷商同意按照附表上列明的公司股份數量，以每股4.185美元的價格從公司購買公司股份（購買價格的93%） 附件1 每股公司股票的購買價格爲$3.72（購買價格的93%）。

1.1.2 股份 付款和交付.

(i)交付 和支付公司股票應在2024年10月15日東部時間上午10:00進行。公司股份的交付和支付時間被稱爲“結束日期。.”

(ii) 在收盤日通過電匯方式支付公司股票，金額以聯邦（同日）資金支付，支付給公司指定的訂單，在遞交代表公司股票的證書（形式和內容應令承銷商滿意）之時（或通過託管信託公司的設施）DTC”負責帳戶的承銷商。公司訂單應註冊以代表所需的名稱或名字和授權面額，代表應在結束日期前至少兩個完整的工作日書面要求。公司不得強制出售或交付公司訂單，除非代表支付所有公司訂單款項。術語“第十章 轉讓證券 第10.1節 交易 如果發行受託人證明，債券持有人可以交換並迅速交付發行受託人這樣的證明，無論是有欠款未償還，還是實質性週轉的時候，都可以在世界範圍範圍內經由源和債券市場交易。業務日是指除了星期六、星期日或法定節假日或紐約州紐約市授權或按照法律必須關閉的銀行機構的日子之外的任何日子。

1.2 超額配售選擇權.

1.2.1 認購權股票爲了覆蓋與公司股份的分銷和銷售相關的任何超額配售，公司特此授予承銷商購買多達322,500股額外普通股的選擇權，這些股份代表發行中銷售的普通股的百分之五（15%），從公司（「超額配售選擇權」）。 這322,500股額外的普通股的淨收益將存入公司的帳戶，下稱爲“認購權股票。每股期權股的購買價格應等於本文件第1.1.1(ii)節中規定的每股公司股份價格。公司股份和期權股下稱爲“公共證券。公開證券的發行和銷售，下稱“增發計劃.”

1.2.2 行使選擇權根據本協議第1.2.1節授予的超額配售選擇權，代表有權在收盤日期後的三十（30）天內行使所有或任何部分的備選股票（隨時）。 在行使超額配售選擇權之前，承銷商無須購買任何備選股票。 本處授予的超額配售選擇權可由代表口頭通知公司行使，必須通過隔夜郵件或傳真或其他電子傳輸進行書面確認，說明要購買的備選股票數量，交付和支付備選股票的日期和時間（“選擇權收盤日”） ，不得晚於通知日期之後的五（5）個全業務日或公司與代表協商同意的其他時間，在公司和代表協商同意的地點（包括通過傳真或其他電子傳輸遠程進行）將發生交付和支付備選股票。 如果備選股票的交付和付款未在收盤日期發生，備選收盤日期將如通知中所述。 在行使超額配售選擇權涉及全部或任何部分備選股票之後，根據本處規定的條款和條件，（i）公司有義務向承銷商出售通知中指定的備選股票數量； 和（ii）每家承銷商單獨而非共同購買當時正在購買的備選股票總數量的部分 按所述 附件1 相反地。

1.2.3 支付和交付。選擇權股票的支付應在選擇權結束日期（就全部適用時間而言）通過向您交付代表選擇權股票的證書（證書形式和合理內容滿意）（或通過DTC的全速傳輸設施或通過DWAC轉移）進行的聯邦（同日）資金劃轉而進行。選擇權股票應根據承銷商事先書面要求註冊在指定號碼和麪值中。本公司應僅在承銷商支付各適用選擇權股票的款項後才有出售或交付選擇權股票的義務。。在認購結束日期，通過電匯方式支付期權股份費用，使用聯邦（當天）資金支付給公司，交付給您代表行認可的證書（形式和內容符合承銷商要求），代表行帳戶內（或通過DTC設施）進行。期權股份應註冊爲代表行書面請求的姓名或姓名以及授權面額，日期前至少一個（1）完整業務日進行。公司不得在未經代表行支付適用期權股份費用的情況下出售或交付期權股份。

1.3 第三方存款協議同時與本協議的執行和交付一起，公司、代表和CFN律師（稱爲“託管代理”）將簽署託管協議（“第三方存款協議”），根據協議，公司應在交割日將$100,000的收益存入一個不支付利息的託管帳戶（稱爲“在交易完成日，母公司將會轉移存放在Escrow Account（託管帳戶）的與2.1(a)款規定相應的總併購代價金額至由公司爲ICCH股東的利益而設立的單獨的付款代理帳戶。”）。截至2025年10月15日（交割後12個月），託管帳戶中未受索賠保護的所有基金將根據託管協議的條款歸還給公司。公司將負責託管代理的費用和支出。

2. 公司的陳述和擔保公司在適用時間（如下所定義），收盤日期以及任何情況下的選擇性收盤日期，向每位承銷商聲明並擔保如下：

2.1 提交註冊聲明.

2.1.1 根據證券法案公司已向美國證券交易委員會（「交易所」）提交了一份「S-3表（文件編號333-261229）」的存檔註冊聲明，包括任何相關的招股書或招股書，以在《證券法》下注冊公共證券，該註冊聲明在所有實質方面都是符合《1933年證券法》（「證券法」）及其修訂案和交易所《證券法》規定的要求，包含並將包含所有必須根據《證券法》和《證券法規》在其中說明的重要聲明。除非上下文另有要求，否則在任何特定時間，根據「S-3表」第12項在《證券法》下提交的文件、陳述和附表，以及根據《證券法規》430億項（「規則430億信息」）或其他根據《證券法規》在該時間被視爲部分內容或包含在其中的文件和信息，均被稱爲「註冊聲明」。註冊聲明在最初生效時被稱爲「註冊聲明」。如果公司根據《證券法規》第462(b)條提交任何註冊聲明，以涉及公共證券，則在此類提交之後，「註冊聲明」的術語將包括根據規則462(b)提交的此類註冊聲明。註冊聲明於2022年6月10日被委員會宣佈生效。委員會:註冊聲明書，並根據1933年修訂版證券法案（以下簡稱「證券法案」）的F-1表（文件編號333-280198）進行修訂，包括任何相關的招股說明書，用於註冊公共證券的登記證券法公司已就「證券法」 在美國證券交易委員會（「交易所」）提交的一份註冊聲明，以及一份或多份修改文件F-1（文件號333-______），包括任何相關招股說明，以申請根據1933年修正法案（「證券法」）註冊的公共證券，所有這些註冊聲明和修改或修改均在所有實質方面均由公司準備，以符合證券法和美國證券交易委員會根據證券法規定的規則和法規。證券法規定將包含所有必須在其中聲明的重要聲明，符合證券法和證券法法規的要求。除非情境另有要求，此類登記聲明在生效之時已提交給委員會（包括在其中包含的初步招股書（如下所定義）、財務報表、日程安排、展覽品以及作爲其一部分或引用在內的所有其他文件以及所有根據證券法規規定的在有效日期根據規則430A第（b）段認定爲其一部分的所有信息）Rule 430A信息”)), 在此稱爲“註冊聲明書公司根據《證券法規定》第462（b）條規定提交任何註冊聲明，則 在此類提交之後，「」術語將包括根據 462（b）條提交的註冊聲明。註冊聲明已於今日被委員會宣佈生效。蘋果公司CEO庫克大規模拋售股票，套現逾3億港元，資金已存入上市公司設立的專項帳戶(「信託帳戶」)，以公共股東(定義詳見下文)爲受益人的註冊聲明(FORM S-1)中所規定的一定金額及特定款項。信託帳戶中持有的基金類型(包括資金持有的利息)除支付公司稅費以外，一旦實現以下最早的情況之一即可支取: (i) 完成首次（業務）組合；(ii) 如果公司未能在2025年3月3日之前完成首次（業務）組合，則可以贖回100%的發行股份（如下所述）；或 (iii) 股東表決贖回發行股份。 若要批准修訂本Amended and Restated Certificate，必須就修訂對決定最早如下情形之一的公司的義務以在首次業務組合中允許贖回或未在終止日期之前完成首次業務組合即贖回100%的發行股份產生影響或涉及股東權益或首次業務組合前的活動（如第9.7節所述），對修訂進行表決。發售期(「發售期」)所出售單位的組成部分的Common Stock股份的持有人(「發售股份」)，不論這些發售股份是在發售期內還是在發售市場上的二級市場中購買，也不論這些持有人是公司的發起人，高管或董事，或上述任何關聯方的子公司，均在此被稱爲「公共股東」。“包括根據規則 462(b)提交的註冊聲明。註冊聲明已於2024年2月28日被委員會宣告生效（“生效日期。”).

在註冊聲明生效前使用的每份招股說明書，以及在生效後但在執行和交付本協議前使用的省去規則430A信息的每份招股說明書，在此均稱爲“初步招股說明書。”於2024年8月29日的初步招股說明書，暫定爲，其在適用時間之前，包含在註冊聲明中，下文稱爲“定價招股書。”根據《證券法》第424(b)條首次提交的最終招股說明書，下文稱爲“招股書。”任何提及「最新初步招股說明書」都應視爲指最新的納入註冊聲明中的初步招股說明書。

“適用時間「」表示東部時間上午9點，本協議日期當天。

“發行人自由撰寫招股說明書「」表示《證券法規定》第433條規則中的任何「無發行人書面招股書」，包括但不限於與公共證券相關的《證券法規定》第405條規則中定義的「無發行人書面招股書」，該書面招股書可能會被公司提交證券交易委員會文件，也可能是根據《證券法規定》第433(d)(8)(i)意義上的寫作形式的「路演」但不一定需提交證券交易委員會文件的，或根據《證券法規定》第433(d)(5)(i)獲得的豁免不必提交證券交易委員會文件的，因爲該書面招股書中包含的公共證券或發售描述不反映最終條款，這些都是根據公司提交或根據《證券法規定》第433(g)在公司檔案中保存的格式。規則433包括但不限於，任何與公司應向委員會提交的《免費書面招股書》（根據《證券法規》第405條規定）有關的公開證券的文件，（i）被公司要求提交給委員會的文件，（ii）根據規定（433(d)(8)(i)條），不管是否被要求提交給委員會的「路演文物交流」，（iii）根據規定（433(d)(5)(i)條）免於提交給委員會的文件，因爲它包含不反映最終條款的公開證券或發行的描述，每種情況均應以提交或應提交給委員會的形式，如果不需要提交，則應以《規則433(g)》公司記錄中保留的形式。

“發行人一般使用的自由寫作招股書“ 指的是任何面向潛在投資者進行一般分發的發行人自由書面意見（Rule 433中定義的「真正的電子路演」除外）誠實的電子路演”），並通過明確指定來證明 時間表2-B 現有信貸協議第10.14條的規定已經納入本協議並適用於本協議。

“發行人有限使用自由書面招股說明書” 表示任何不屬於發行人通用自由書面勾勒的發行人免費書面勾勒。

“定價透明度包在適用時間點或之前發行的任何發行人普通使用的免費書面募集招股說明書，定價書面募集招股說明書和包含的信息 附表2-A 所有板塊一起考慮。

2.1.1 根據證券交易法公司已向委員會提交了一份8-A表格（文件編號001-42362），根據1934年修訂版證券交易法第12（b）條的規定進行註冊。普通股在交易所法案下的註冊已被委員會宣佈在此日期之前生效。公司沒有采取任何旨在終止普通股在交易所法案下注冊，或可能產生此效果的行動，也沒有收到委員會正在考慮終止該註冊的任何通知。使擁有公司註冊證券類別10%以上股權的官員、董事或實際股東代表簽署人遞交表格3、4和5（包括修正版及有關聯合遞交協議）,符合證券交易法案第16(a)條及其下屬規則規定的要求；無

2.2 目錄。這些普通股已獲得納斯達克資本市場上市批准（“交易所並且公司未採取任何旨在或可能導致公司股票在交易所退市的措施，也未收到交易所正在考慮終止上市的任何通知，除非在註冊聲明、定價披露文件和招股說明書中另有說明。

2.3 沒有止損訂單，以太經典。 無論聯邦貿易委員會或者, 根據公司的了解，任何州監管機構均未發佈任何阻止或暫停使用註冊聲明、任何初步招股說明書或招股書的命令，也未進行或, 根據公司的了解, 威脅要發起與此類命令相關的任何程序。公司已遵守聯邦貿易委員會要求的每一個（如果有的話）額外信息。

2.4 註冊聲明中的披露 .

2.4.1 遵守證券法和100億.5代表.

(i) 每個註冊聲明及任何生效後的修正，生效時，均在所有重要方面符合《證券法》和《證券法規》的要求。每份初步招股說明書，包括最初提交或作爲註冊聲明的一部分提交或修正或補充的招股說明書，以及招股說明書，在提交給委員會時，在所有重要方面均符合《證券法》和《證券法規》的要求。交付給承銷商用於本次發行的每份初步招股說明書和招股說明書與通過EDGAR根據Regulation S-t提交給委員會的電子傳輸副本完全相同，除了根據S-t規定的範圍。

(ii) 在生效時間、適用時間、結束日期或任何期權結束日期（如有）時，註冊聲明或其中任何修正案均不包含或將不包含關於實質事實的虛假陳述，也未或將未包含必須在其中聲明的實質事實或必要使其中陳述不誤導的事實。

(iii) 定價披露文件，在適用時間，於收盤日期或任何期權收盤日期（如有），沒有包含、並且不會包含任何重大事實的不實陳述或遺漏了必要的重大事實，以使其中的陳述在進行其所作陳述的情況下，不具誤導性；並且每家發行人此處使用的有限使用自由書面招股書與註冊聲明、任何初步招股書、定價招股書或招股說明書中的信息不相沖突，每份此類發行人有限使用自由書面招股書，在適用時間，經由定價招股書補充，作爲整體閱讀，沒有包含任何重大事實的不實陳述或遺漏了必要的重大事實，以使其中的陳述在進行其所作陳述的情況下，不具誤導性； 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。此聲明和保證不適用於在依賴於代表向公司提供的與承銷商有關的書面信息並符合註冊聲明、定價招股說明書或招股說明書或其任何修正或補充時作出或省略的陳述的情況。各方承認並同意，由任何承銷商或代表提供給公司的信息僅包括招股說明書「承銷」部分中包含的以下披露（“承銷商信息淨有形資產完成條件

(iv) 無論是招股說明書，還是就此作出的任何修改或補充（包括任何招股說明書封皮），其發行日期、根據424(b)規則向委員會提交任何備案文件時、收盤日期或任何行權收盤日期，都未包含或將不包含任何重大事實的虛假陳述或未包括、遺漏或將遺漏必要的重大事實以便根據製作時的情況，這些陳述不會產生誤導；但是，此陳述和擔保不適用於承銷商信息。

2.4.1 協議披露註冊聲明、定價披露文件和招股說明書中描述的協議和文件在所有重大方面與其中包含的描述一致，並且在註冊聲明、定價披露文件和招股說明書中根據《證券法》和《證券法規》要求描述或作爲註冊聲明的附件提交給委員會的協議或其他文件中沒有未被描述或提交的協議或其他文件。公司作爲一方的每份協議或其他文件（不論其如何分類或描述），對公司具有法律約束力或可能對公司具有法律約束力，並且（i）已作爲註冊聲明、定價披露文件和招股說明書的附件提交，或（ii）對公司的業務具有重要意義的協議或文件，已經得到公司的妥善授權和有效簽署，具有所有重大方面的法律約束力，並且對公司和據公司所知的其他相關方具有根據其條款產生的強制執行效力，除非（x）此類強制執行可能受限於影響債權人權利的破產、無力支付、重組或類似法律，（y）根據聯邦和州證券法，任何償還或提供補償規定的可執行性可能受到限制，（z）特定執行和禁令等形式的補救措施可能受到法庭審理該等訴訟前的衡平抗辯和自由裁量的限制。沒有這類協議或文件已轉讓給公司，公司或據公司所知的其他任何方均沒有違約，據公司所知，沒有發生任何事件會構成該等協議違約，儘管隨時間流逝或通知發出，或兩者均發生，會構成該等違約。據公司最好的了解，公司履行此類協議或文件的重大規定不會導致違反任何現行適用的任何法律、規則、條例、判決書、命令或任何國內、外政府機構或法院有管轄權的法規，也不會違反公司或其資產或業務之一上述法院有管轄權的任何現有適用法律、規則、條例、判決書、命令或法令（即“"}政府實體包括但不限於與環保法律法規相關的條款。

2.4.2 監管。i.定價透露包和招股說明書中有關聯邦、州、地方和所有外國監管對發售和公司業務及當前考慮的業務的影響的披露在所有方面正確無誤，根據證券法在註冊聲明、定價透露包或招股說明書中沒有需要披露的其他監管規定，其未作披露。ii.除了在定價透露包和招股說明書中描述的情況之外，公司和其受控實體已遵守，已採取所有步驟確保其股東、董事和高管（以P制定或直接或間接擁有或受控的PRC居民或公民爲特定人員）遵守適用於適用的規則和條例，而這些規則和條例是適用於適用的關閉日期，以近期發展的規模爲準，涉及到有關海外投資的PRC居民和公民（「PRC海外投資和上市管理條例」），其中包括要求P制定或直接或間接擁有或受控的PRC公司或個人在海外投資和上市管理條例下向適用的PRC政府機構進行任何註冊和其他程序（包括SAFE的任何適用規則和法規）。根據協議日期前三（3）年開始的期間內，公司未出售任何證券，也沒有由公司或代表公司，或者爲了公司或公司受控的、被控制的或與公司共同受控的任何人或人士出售，除非在註冊聲明書、定價披露文件和初步招股說明書中披露。

2.4.3 《法規》。註冊聲明書、定價披露文件和招股說明書中關於聯邦、州、地方法規對發行和公司業務的影響的披露在各方面均正確，目前已考慮的內容均正確，並且註冊聲明書、定價披露文件和招股說明書中沒有需要披露但未在其中披露的其他法規。

2.5 更改 在登記聲明書中的日期後.

2.5.1 無實質不利變動從在證券登記申報書、定價披露文件和招股說明書中提供信息的各自日期起至今，除非在其中另有具體說明：（i）公司的財務狀況或營運結果沒有發生重大不利變化，也沒有任何可能單獨或合計涉及公司情況（財務或其他方面）、營運結果、業務、資產或前景出現重大不利變化或潛在重大不利變化；（ii）公司沒有進行任何重大交易，除非根據本協議的安排；以及（iii）公司沒有任何董事或董事候選人辭去公司的任何職位。重大不利變化」；（ii）公司未進行任何重要交易，除本協議規定外；以及（iii）公司任何職員或董事未辭去任何公司職位。

2.5.2 最近的證券交易等。 根據在登記申明書、定價披露包和招股書中提供資料的相應日期，並且除非在此特別說明或在登記申明書、定 價披露包和招股書中另有指示，公司並未：(i) 發行任何證券或承擔任何直接或間接的借款債務；或 (ii)宣 布或支付股息或進行其他任何關於其股本的分配。

2.6 獨立會計師就公司了解，Enrome LLP (「本報告」) 是一家獨立註冊的公共會計師事務所，根據證券法及證券法規定以及公開公司會計監督委員會的要求，在提交給委員會的登記聲明、定價披露文件以及招股說明書中。審計師在登記聲明、定價披露文件和招股說明書中涵蓋的財務報表所涵蓋的期間內，未向公司提供任何非審計服務，此術語如在《交易所法》第10A(g)條中使用。審計員就公司了解，Enrome LLP (「本報告」) 是一家獨立註冊的公共會計師事務所，根據證券法及證券法規定以及公開公司會計監督委員會的要求，在提交給委員會的登記聲明、定價披露文件以及招股說明書中。審計師在登記聲明、定價披露文件和招股說明書中涵蓋的財務報表所涵蓋的期間內，未向公司提供任何非審計服務，此術語如在《交易所法》第10A(g)條中使用。

2.7 財務報表等。 財務報表，包括註冊聲明、價格披露內的附註及附表 套件和招股章程序，公平地呈現本公司於當日期及以下的財務狀況及營運結果 其適用的期間；而該等財務報表已按照美國一般公認的會計原則擬備 (」高爾夫」)，在相關期間一致地應用（前提是未經審核中期財務報表） 受到年終審計調整，預計總計不會具有重要性，並且不包含所有必要的註腳 通過 GAAP）；以及註冊聲明中包含的附屬表，公平地呈現在該聲明所需的資料。 除其中包含的情況外，註冊聲明不需要包含任何歷史或專業財務報表， 根據《證券法》或《證券法》規定的價格披露套件或招股章程。專案和專案 作為註冊聲明、價格披露套件中包含的調整財務資料及相關附註 (如有) 以及本招股章程已根據《證券法》及《證券法》的適用要求，妥善編制及編製本招股章程 《證券法規例》並公平地呈現其所載的資料，以及編制該條例時所使用的假設是合理的 以及其中所使用的調整適當，以實現該內容所提及的交易和情況。所有披露 包含在註冊聲明、價格披露套件或有關「非 GAAP 財務措施」的招股章程 （由於該術語由委員會的規則和規例定義），如有，遵守交易法和項目的 G 條 《證券法》第 S-k 條第 10 條，在適用範圍內。每份註冊聲明、價格披露套件 以及本章程說明所有重大資產負債表外交易、安排、義務（包括可定義務）， 以及本公司與未合併實體或其他人士之關係，而其他可能會產生重大目前或未來影響 關於公司財務狀況，財務狀況的變化，營運結果，流動性，資本支出，資本 資源，或收入或支出的重要組成部分。除註冊聲明中所述的情況外，價格披露 套件和招股章程，(a) 本公司及其任何直接和間接附屬公司，包括披露的每個實體或 註冊聲明、價格披露套件和招股章程中描述為本公司的附屬公司（每一個、 一」子公司」以及集體而言，」子公司」)，已承擔任何重大責任或 義務（直接或有條件），或進行其他在普通業務過程以外的任何重大交易，(b) 本公司 沒有就其資本股票申報或支付任何股息，或作出任何形式的分配，(c) 沒有 本公司或其任何附屬公司資本股的任何變化，或在業務過程以外，以下任何補助金 任何股票補償計劃，以及 (d) 本公司的長期內沒有發生任何重大不利變化或有 本公司對財務報告的內部控制方面沒有任何改變，並不會產生重大或不利影響，或有合理的影響 可能會對本公司對財務報告的內部控制進行實質和不利影響。

2.8 授權資本；期權，以太經典公司在註冊聲明書、定價披露文件和招股說明書指定的日期或日期具有duly授權、發行和流通中的資本結構。根據註冊聲明書、定價披露文件和招股說明書中所述的假設，公司將在收盤日期擁有其中列明的調整後的股本結構。除註冊聲明書、定價披露文件和招股說明書中所列明的或所設想的情況外，在有效日期、適用時間以及收盤日期和任何期權收盤日期，不會有股票期權、認股權證或其他購買或以其他方式取得公司已授權但未發行的普通股或可轉換成公司普通股或可行權的任何安全性，或任何發行或銷售普通股或任何此類期權、權證、權利或可轉換證券的合同或承諾。

2.9 有效 證券發行等

2.9.1 優秀證券所有已發行和流通的公司證券均已經獲得充分授權並已發行，均已全額支付且無需進一步徵收; 持有人在此方面無撤銷權，並且不因爲是這樣的持有人而受到個人責任的約束; 而且未違反公司的任何已發行證券的優先購買權或公司授予的類似合同權利。已獲授權的普通股在所有重要方面均符合註冊聲明、定價披露文件和招股書中有關其內容的陳述。已發行的普通股的發售在所有相關時段，要麼已在證券法和適用州證券或「藍天」法下注冊，要麼基於購買者對這些股份作出的陳述和保證免除了該等註冊要求。

2.9.2 根據本協議出售的證券已經妥善授權發行和銷售公共證券，發行並支付後，將被有效發行，完全支付且不可評定; 持有人不會因爲作爲持有人而承擔個人責任; 公共證券不會受到公司任何證券持有人的優先購買權或類似合同權利的個人責任; 並且對於公共證券的授權、發行和銷售已經妥善並有效地採取所有法定公司行動。 公共證券在註冊聲明、定價披露文件和招股說明書中就此包含的所有聲明中，在所有重大方面符合。

2.10 第三方的註冊權除非在註冊聲明、定價披露文件和招股說明書中另有規定，公司的任何證券持有人或任何可行權轉換爲公司證券的權利持有人均無權要求公司根據證券法註冊任何此類公司證券，或將任何此類證券包括在公司將要提交的註冊聲明中。

2.11 協議的有效性和約束力。每項協議和第三方擔保協議已獲得公司的有效授權，當簽訂和交付後，將構成公司的有效和具有約束力的協議，根據各自的條款，公司有權強制執行，除非：(i)受到影響債權人權利的破產、無力償還、重組或類似法律的限制；(ii)任何賠償或貢獻條款的可執行性可能受到聯邦和州證券法的限制；以及(iii) 特定履行和禁止性和其他形式的衡平救濟可能受到衡平辯護和法院裁量權的約束，應依據任何可能提交上述申請的法院決定。

2.12 沒有衝突等公司對本協議及所有附屬文件的執行、交付和履行，對本協議及所述交易的完成，公司對本協議及上述文件條款的遵守均不會且不會導致有或不經事先通知或經過時間流逝或二者同時： (i) 構成重大違約行爲、或與任何協議或文件的條款和規定發生衝突、或構成重大違約，或根據公司是一方的任何協議或文件條款依據而在任何財產或資產上創建、修改、終止或施加任何留置權、抵押或負擔； (ii) 違反公司的公司章程（或不時經修訂或重訂的同一文件，「」）的規定；或 (iii) 違反任何現有適用法律、規則、法規、判決、命令或法院的判決，截至本協議日期，但是在(i)和(iii)項的情況下，除了任何可能導致單獨地或合計形成重大不利變化的違約、衝突、違反、違約、留置權、抵押或負擔的情況外。掌管文件”); 或 (iii) 違反任何現行適用的法律、規則、法規、判決、命令或政府實體的法令，截至本日期，但在(i) 和(iii)一、或兩種違約、衝突、違背、留置權、抵押或負擔的情況下，不可能合理地導致重大不利變化。

2.13 沒有違規行爲；違規行爲沒有任何實質性違約存在，該違約涉及公司作爲一方或公司的資產可能受約束的任何其他重要協議或休息曲約或條件的履行和遵守，包括任何重要許可證、合同、契約、抵押、信託契約、票據、貸款或信貸協議，或任何其他借款義務的協議或文件。 公司不違反其公司文件的任何條款或規定，也沒有違反任何特許經營權、許可證或許可證，也沒有違反適用法律、法規、規章、判決或政府實體的法令，除了在第(ii)和(iii)項中，對於不太可能導致單獨或總體上產生實質性不利變化的任何違反。

2.14 公司權力；許可；同意.

2.14.1 業務行爲的處理除非在註冊聲明書、定價披露文件和招股說明書中另有描述，公司具有所有必要的公司權力和權限，並具有所有必要的法律授權、批准、命令、許可證書和許可證，從所有政府監管官員和機構獲得截至本日期需要開展業務目的的授權，如註冊聲明書、定價披露文件和招股說明書中所述。

2.14.2 本協議設定的交易該公司擁有全部法定權力和授權進入本協議並執行本協議的條款與條件，已獲得與此相關的所有同意、授權、批准和所需訂單。對於發行、銷售和交付公共證券以及本協議和註冊聲明、定價披露文件和招股說明書中所考慮的交易和協議的完成，並未需要任何法院、政府機構或其他機構的同意、授權或訂單，也不需要提交任何文件，除非已獲得或提交了（i）已經獲得或提交的同意、批准、授權、訂單、提交、註冊或資格，以及（ii）關於適用聯邦和州證券法律以及金融業監管局規則和規例。FINRA”).

2.15 D&O 問卷調查。至 公司的知識，每個人填寫的問卷（「問卷」）中包含的所有信息 本次發行前的公司董事和高級職員（”內部人士”) 由所有人補充 註冊聲明中描述的有關公司董事、高級管理人員和主要股東的信息， 定價披露一攬子計劃和招股說明書以及封鎖協議（定義見下文第2.24節）中提供給 承銷商在所有重要方面都是真實和正確的，公司尚未得知任何可能導致的信息 問卷中披露的信息變得嚴重不準確和不正確。

2.16 訴訟；政府行政程序。 沒有任何訴訟、行動、訴訟、詢問、仲裁、調查、訴訟或政府程序，現在公司知道的，針對公司或公司的任何高管或董事而無待決或威脅，或是未在《註冊聲明書》、定價披露文件和招股說明書中披露，或是未在公司提交上市申請的過程中披露，除非不能合理預期，這些情況將單獨或合併對公司造成重大不利變化。

2.17 有效公司已依法組織，作爲一家公司正當存在於開曼群島法律下，並且在 date履行良好，並且已經合法取得資格在需要註冊的其他司法管轄區從事業務，除非未獲得合格，單獨或合計， 不會合理預期造成重大不利變化。

2.18 保險公司有權享受保險的益處，公司知道，保險人是著名的保險機構，涵蓋了公司認爲足夠的金額和風險，包括但不限於至少達到50萬美元的董事和管理人員保險覆蓋，並且公司已將每位承銷商列爲董事和管理人員保險覆蓋的受保險方，所有這些保險均有效無誤。公司沒有理由認爲無法（i）在保單到期時續保現有的保險覆蓋，或者（ii）從類似的機構獲得類似的保險覆蓋，以便按照目前的方式經營業務，並且成本不會導致重大不利變化。

2.19 交易 影響向FINRA披露.

2.19.1 向協助介紹投資者認識發行人的人支付佣金必須遵守適用的法律。在向美國人出售的股票中，未在美國證券交易所法案及適用州證券法修改案下注冊爲經紀商的人亦未能獲得佣金，除非這樣的獲得者豁免於該等註冊要求。除非在註冊聲明書、定價披露文件和招股說明書中另有說明，否則不存在任何與公司或任何內部人員有關的查找人員、諮詢或發起費用支付的申索、支付、安排、協議或諒解，涉及根據本次公開發行出售的證券或公司的其他安排、協議或諒解，或根據公司或公司所知，可能影響承銷商報酬的任何股東的安排、協議或諒解。

2.19.2 十二個月內的付款除註冊聲明書、定價披露文件和招股說明書中所述外，公司在生效日期前十二（12）個月內未向任何人直接或間接支付過現金、證券或其他形式的費用，作爲尋找費、諮詢費或其他形式的酬金，用以考慮這樣的人爲公司籌集資本或向公司引薦爲公司籌集資本的人，或者引薦爲公司提供資本的人；未向任何金融業監管局成員支付過現金、證券或其他形式的費用；未向在生效日期前十二（12）個月內與任何金融業監管局成員有直接或間接從屬關係或聯繫的任何人或實體支付過費用，除了根據本Offering文件向承銷商支付之外的費用。

2.19.3 使用所得款項。公司不會向任何參與FINRA成員或其關聯公司支付本次發行的淨收益，除非在本文件中另有特別授權。

2.19.4 FINRA的隸屬關係。沒有任何公司未註冊證券的董事、高管或10%或更多的受益所有人與參與成員(根據FINRA規則定義)有任何直接或間接的隸屬或關聯。如果公司了解到任何擁有10%或更多未註冊普通股的高管、董事或業主與參與成員或已註冊人員有關聯或成爲其附屬機構，公司將告知代表和Sichenzia Ross Ference Carmel LLP。除非在註冊聲明、定價披露文件和招股說明書中另有說明，公司所知，公司沒有（i）公司的高級管理人員或董事，（ii）持有公司任何類別證券10%或更多權益的實益所有人，或（iii）在註冊聲明提交前180天內取得公司非註冊股權證券的實益所有人，該實益所有人是FINRA成員參與本次發行的關聯人或關聯方（根據FINRA的規定和法規確定）。

2.19.5 信息就公司所知，公司在其提交給Haneberg Hurlbert PLC的FINRA問卷中提供的所有信息，專門供承銷商律師在進行與其公開發行系統申報（及相關披露）有關的工作時使用，就所有重要方面都是真實、正確且完整的。承銷商的法律顧問

2.20 《反海外賄賂法》。公司及其子公司，截至目前，不知悉有任何董事、高級管理人員、代理人、僱員或附屬公司的關聯方或任何代表公司及其子公司行事的其他人，直接或間接向任何客戶、供應商、僱員或代理人、任何政府機構的官員或僱員（國內或國外）或任何政黨或競選中的候選人或其他有可能協助或妨礙公司業務（或協助其就任何實際或擬議的交易提供幫助）的人士提供或同意提供任何金錢、禮物或類似的利益（除了在業務日常運營中向客戶合法的價格優惠）。該等行爲可能會使公司在任何民事、刑事或政府訴訟程序中受到損害或處以罰款；如果過去未提供，可能導致重大不利變化；如果未來未繼續提供，可能對公司的資產、業務運營或前景產生不利影響。公司已採取合理措施，確保其會計控制和程序足以使公司在所有重大方面遵守1977年修正版的《1977年反海外腐敗實踐法》。

2.21 OFAC合規公司及其附屬公司，或據公司所知，公司及其附屬公司的任何董事、高級職員、代理人、僱員或關聯公司，以及代表公司及其附屬公司行事的任何其他人，目前未受美國財政部外國資產控制辦公室實施的任何制裁。OFAC，公司也不會，直接或間接，使用本次發行的收益，或將這些款項貸款、捐助或以其他方式提供給任何子公司、合資創業公司夥伴或其他人或實體，用於資助任何目前受美國財政部海外資產控制辦公室制裁的個人的活動。

2.22 反洗錢法公司及其子公司的運營始終以符合適用的《貨幣和外國交易報告法》以及所有適用司法管轄區的反洗錢法規的財務記錄保存與報告要求，以及任何相關或類似的規則、法規或指南，由任何政府實體（統稱“反洗錢法洗錢法”）；且就涉及公司與反洗錢法律事務的任何政府實體提起或涉及的訴訟或訴訟程序，據公司最佳了解，目前沒有未決事項或威脅。

2.23 官員證明任何由公司任何授權人簽署並交付給您或承銷商律師的證書應被視爲公司向承銷商就其中涵蓋事項作出的陳述和保證。

2.24 鎖定協議。 附表3 此處包含了公司官員、董事名單的準確清單，據公司所知，包括持有超過公司已發行普通股5%以上記錄的持有人，轉換或行使爲普通股的證券，以及公司的某些其他股東（統稱爲“鎖定方”，公司已要求每位限制出售方向代表交付經執行的限售協議，形式附在此處 附錄 A(c)雙方確認公司已於2024年5月6日撤銷了Triller LLC 2024 S-1的申報。鎖定協議鎖定協議

2.25 子公司所有直接和間接子公司已根據其組織或註冊地的法律合法組織並處於良好狀態，並且每個子公司在其擁有或租賃財產或開展業務所需的每個司法管轄區均處於良好狀態，除非未取得資格不會造成重大逆轉變化。公司對每個子公司的所有權和控制情況如註冊聲明、定價披露文件和招股說明書中所述。

2.26 關聯交易公司或任何其他相關人士在註冊聲明、定價披露文件和招股說明書中需要描述但尚未描述的業務關係或關聯交易均不存在。

2.27 董事會公司的董事會由《定價招股說明書》和題爲「管理層」的招股說明書規定的人員組成。擔任董事會成員的個人資歷以及董事會的整體構成符合《交易所法》，符合委員會制定的規則和法規。交易所法規》，《薩班斯-豪利法案》及根據其制定的規則（“《薩班斯-奧克斯利法案》》交易所的上市規則。公司的董事會審計委員會中至少一名成員符合「審計委員會財務專家」的資格要求，該術語的定義參照S-K法規和交易所的上市規則。此外，擔任董事會成員的至少半數符合《交易所的上市規則》所定義的「獨立」資格。

2.28 公司符合2002年Sarbanes-Oxley法案的所有適用要求，該法案於今日起生效，所有適用的委員會規則和規定自今日起及截止日和期權截止日生效。.

2.28.1 披露控制公司已開發並當前維護的信息披露控制和程序將符合《交易所法》第13a-15條或15d-15條規定，並且這些控制和程序有效確保使有關公司的所有重要信息及時知曉，以便公司交易所法文檔和其他公開信息披露文件的編制負責人。

2.28.2 合規性本公司在適用時期或收盤日將在實質上遵守薩班斯-豪利法案的相關規定，該法案當時有效，並且該公司被要求在適用時期或收盤日遵守，並已實施或將實施這些程序，並採取合理措施，以確保公司未來遵守薩班斯-豪利法案的所有重要規定（不晚於相應的法定和監管截止日期）。

2.29 會計控制公司及其子公司保持符合《交易所法規》規定的「財務報告內部控制」體系，並由其相應的首席執行官和首席財務官或執行類似職能的人員設計或監督，以在符合GAAP的情況下爲外部目的編制財務報表提供合理保證，包括但不限於足以提供合理保證的內部會計控制，即：(i) 交易按照管理層的一般或具體授權進行; (ii) 交易記錄必要以便依照GAAP編制財務報表和維護資產賬務; (iii) 只有按照管理層的一般或具體授權才允許訪問資產; (iv) 資產的記錄賬務定期與現有資產進行合理比較，並對任何差異采取適當措施。除在註冊聲明、定價披露文件和招股說明書中披露的內容外，公司不知悉其內部控制方面是否存在任何重大弱點。據公司所知，公司的核數師和公司董事會審計委員會已被告知：(i) 所有對公司財務報告內部控制設計或操作方面產生不利影響或可能對公司記錄、加工、彙總和報告財務信息的能力造成不利影響的重大缺陷和重大弱點，是已知的公司管理層已知曉的; (ii) 所有公司管理層已知曉的涉及公司內部財務報告控制的管理層或其他僱員的欺詐行爲，無論是否重大。儘管以上規定，本協議中的任何內容均不要求公司遵守薩班尼斯-豪利法案第404條以及與之相關的規則和法規及較早日期的規定，除非公司根據適用法律必須在此之前履行。

2.30 無投資公司地位公司在進行發行以及利用所得款項如註冊聲明書所述，並根據定價披露指引文件和招股說明書的規定後，無需註冊爲根據1940年修正版的《投資公司法》中定義的「投資公司」之一。

2.31 沒有勞工糾紛公司或其附屬公司的員工之間不存在勞資糾紛，據公司所知，目前也沒有即將發生的糾紛。

2.32 知識產權。這個 公司及其每家子公司擁有或擁有或擁有使用所有專利、專利申請、商標、服務的有效權利 商標、商標名稱、商標註冊、服務商標註冊、版權、許可、發明、商業祕密和類似權利 （”知識產權”) 目前爲公司及其子公司開展業務所必需的 繼續執行，如註冊聲明、定價披露一攬子計劃和招股說明書中所述。據我所知 公司，公司或其任何子公司沒有必要採取任何行動或使用來開展其目前的業務 如註冊聲明和招股說明書中所述，將涉及或引發任何侵權行爲、許可證或類似行爲 他人任何知識產權的費用，註冊聲明、定價披露套餐中另有規定的除外 和招股說明書。公司及其任何子公司均未收到任何指控此類侵權行爲、費用或衝突的通知 主張他人的知識產權。除非個人或總體上無法合理預期會產生這樣的結果, 據公司所知，在重大不利變更 (A) 中，沒有第三方的侵權、挪用或違規行爲 本公司擁有的任何知識產權；(B) 沒有待處理的知識產權，據本公司所知，沒有受到威脅 其他人質疑公司在任何此類知識產權中的權利或對該等知識產權的權利提起的訴訟、訴訟、訴訟或索賠，以及 公司不知道有任何事實可以構成任何此類索賠的合理依據，無論是個人還是總體而言， 連同本第 2.32 節中的任何其他索賠，可以合理預期會導致重大不利變化；(C) 知識產權 公司擁有的產權，據本公司所知，許可給公司的知識產權均具有 沒有被具有司法管轄權的法院裁定爲全部或部分無效或不可執行，也沒有待審案件或 其他人質疑任何此類知識產權的有效性或範圍的公司知情、威脅採取的行動、訴訟、訴訟或索賠 產權，而且公司不知道有任何事實可以構成個人索賠的合理依據 或總體而言，加上本第 2.32 節中的任何其他索賠，有理由預計將導致重大不利變化； (D) 沒有其他人對本公司提起的未決訴訟、訴訟、訴訟或索賠，據本公司所知 侵犯、挪用或以其他方式侵犯他人的任何知識產權或其他所有權，本公司有 沒有收到任何有關此類索賠的書面通知，並且公司不知道有任何其他事實可以構成任何索賠的合理依據 此類索賠，無論是單獨還是總體而言，加上本第 2.32 節中的任何其他索賠，都有合理的預期 導致重大不利變化；而且（E）據公司所知，本公司沒有員工違反或從未有過違規行爲 在任何僱傭合同、專利披露協議、發明轉讓協議、競業禁止的任何實質性方面 協議、非招攬協議、保密協議或任何與前僱主簽訂或與前僱主簽訂的限制性協議（以此爲依據） 此類違規行爲與該員工在公司的工作或該員工在公司工作期間採取的行動有關 可以合理地預期公司，無論是單獨還是總體而言，都將導致重大不利變化。致公司的 知識，所有由公司開發和屬於本公司但尚未獲得專利的材料技術信息均已保密。 本公司不屬於任何人的知識產權方面的任何期權、許可或協議的當事方或受其約束 註冊聲明、定價披露一攬子計劃和招股說明書中要求列出的其他個人或實體 並且未在其中描述。註冊聲明、定價披露一攬子文件和招股說明書包含所有重要方面 對前一句所述事項的描述相同。該公司採用的任何技術均未獲得 或者被公司用於違反對公司具有約束力的任何合同義務，或者據公司所知， 其任何高級職員、董事或員工，或以其他方式侵犯任何人的權利。

2.33 稅收除了不可能對公司造成重大不利變化的情況外，公司及其所有子公司已經（i）在此之前向稅務部門申報的所有應申報的報表（如下文所定義）已填寫並繳納或已經獲得延期提交的批准；並且（ii）已支付所有應在該報表中列明的稅款（下文所定義）以及已支付公司或各自子公司徵收的稅金，除非正在善意爭議中且基於基本會計準則在公司的財務報表中已創建了相應準備金。在或作爲註冊聲明的一部分提交的財務報表上顯示的待繳稅款（如果有）足以彌補所有應計及未支付的稅款，無論是否有爭議，並且截至該統一財務報表的日期及之前的所有期間。除在書面形式披露給承銷商之外，（i）任何稅務部門未在與公司或其子公司需支付的任何報表或稅款有關的問題（當前懸而未決），以及（ii）未向公司或其子公司提出有關報表提交或稅款收取方面訂立的免除時效法令的申請。 「稅款」一詞包括所有聯邦、州、地方、外國和其他的淨利潤、毛收入、毛收益、銷售、使用、徵收、轉讓、特許、利潤、許可、租金、服務、使用費、預扣、工資、就業、消費稅、解僱金、印花稅、職業、保險費、財產、意外利潤、關稅、稅務或其他類型的稅款、費用、評估或任何形式的收費，連同任何利息和罰款、稅款追加或其他相關額外金額。"報表"一詞包括提交和應提交的與稅收有關的所有報表、聲明、報告、陳述和其他文件。

2.34 ERISA Compliance. The Company is not subject to the Employee Retirement Income Security Act of 1974, as amended, or the regulations and published interpretations thereunder.

2.35 Compliance with Laws. The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (“Applicable Laws”), except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from any other Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding that if brought, would result in a Material Adverse Change; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Entity is considering such action; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).

2.36 Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.

2.37 Real Property. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.

2.38 Contracts Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company’s or its Subsidiaries’ liquidity or the availability of or requirements for their capital resources required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have not been described as required.

2.39 Loans to Directors or Officers. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers or directors of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

2.40 Smaller Reporting Company. As of the time of filing of the Registration Statement, the Company was a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act Regulations.

2.41 Industry Data. The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.

2.42 Emerging Growth Company. From the time of initial confidential submission of a registration statement relating to the Ordinary Shares with the Commission (or, if earlier, the first date on which a Written Testing-the-Waters Communication, as defined in Section 2.43 below, was made) through the date hereof, the Company has been and is an “emerging growth company” as defined in Section 2(a)(19) of the Act (an “Emerging Growth Company”).

2.43 Testing-the-Waters Communications. The Company has not (i) alone engaged in any Testing-the-Waters Communications, other than Testing-the-Waters Communications with the written consent of the Representative and with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company confirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule 2-C hereto. “Written Testing-the-Waters Communication” means any Testing-the- Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act. “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Rule 163B of the Securities Act.

2.44 Electronic Road Show. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of the Securities Act Regulations such that no filing of any “road show” (as defined in Rule 433(h) of the Securities Act Regulations) is required in connection with the Offering unless such filing has been made.

2.45 Margin Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Ordinary Shares to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

2.46 Regulatory Filings. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its Subsidiaries has failed to file with the applicable Governmental Entity any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Change; except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, all such filings, declarations, listings, registrations, reports or submissions were in material compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not result in a Material Adverse Change.

2.47 Environmental Laws. Except as set forth in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company and its Subsidiaries (i) are in compliance with any and all applicable Federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (ii) have received and are in compliance with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct its business as described in the Registration Statement, the Pricing Disclosure Package or the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.

2.48 Cybersecurity. The Company’s and its Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted, and, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its Subsidiaries have implemented commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); (iv) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. Except as disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, there have been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.

2.49 Compliance with Data Privacy Laws. The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state and Federal data privacy and security laws and regulations, including, without limitation, HIPAA, and the Company and its Subsidiaries are in compliance with the GDPR as applicable (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company and its Subsidiaries have, to the knowledge of the Company, at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.

3 Covenants of the Company. The Company covenants and agrees as follows:

3.1 Amendments to Registration Statement. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Representative shall reasonably object in writing.

3.2 Federal Securities Laws

3.2.1 Compliance. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will, during the period required to permit the completion of the Disclosure Package and the Prospectus, notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of the receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement; and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Public Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use its reasonable best efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

3.2.2 Continued Compliance. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (“Rule 172”), would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of its intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters shall reasonably object.

3.2.3 Exchange Act Registration. For a period of three (3) years after the date of this Agreement, the Company shall use its reasonable best efforts to maintain the registration of the Ordinary Shares under the Exchange Act. The Company shall not deregister the Ordinary Shares under the Exchange Act without the prior written consent of the Representative.

3.2.4 Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Underwriters as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

3.2.5 Testing-the-Waters Communications. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

3.3 Delivery to the Underwriters of Registration Statements. The Company has delivered or made available or shall deliver or make available to the Representative and Underwriters’ Counsel, upon request and without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters, upon receipt of a written request therefor. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

3.4 Delivery to the Underwriters of Prospectuses. The Company has delivered or made available or will deliver or make available to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

3.5 Effectiveness and Events Requiring Notice to the Representative. The Company shall notify the Representative immediately and confirm the notice in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the filing with the Commission of any amendment or supplement to the Registration Statement or Prospectus; and (v) of the receipt of any comments or request for any additional information from the Commission. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.

3.6 Review of Financial Statements. For a period of three (3) years after the date of this Agreement, the Company, at its expense, shall use its reasonable best efforts to cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s financial statements for each of the three (3) fiscal quarters immediately preceding the announcement of any quarterly financial information.

3.7 Listing. The Company shall use its reasonable best efforts to maintain the listing of the Ordinary Shares (including the Public Securities) on the Exchange for at least three (3) years from the date of this Agreement.

3.8 Indemnification Escrow. The Company agrees to set aside from the gross proceeds raised pursuant to this Offering, an aggregate amount of $100,000, to be placed in the Escrow Account under the terms of the Escrow Agreement to be entered into as of the date hereof between the Company, the Representative, and the Escrow Agent, for a period of 12 months  from the date hereof.

3.9 Reports to the Representative.

3.9.1 Periodic Reports, etc. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) a copy of each registration statement filed by the Company under the Securities Act; and (v) such additional documents and information with respect to the Company and the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably request; provided the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable to the Representative and Underwriters’ Counsel in connection with the Representative’s receipt of such information. Documents filed with the Commission pursuant to its EDGAR system (or with respect to articles and press releases, posted on the Company’s website) shall be deemed to have been delivered to the Representative pursuant to this Section 3.9.1.

3.9.2 Transfer Agent; Transfer Sheets. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer agent and registrar acceptable to the Representative (the “Transfer Agent”) and shall furnish to the Representative at the Company’s sole cost and expense such transfer sheets of the Company’s securities as the Representative may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Vstock Transfer, LLC is acceptable to the Representative to act as Transfer Agent for the Ordinary Shares.

3.9.3 Trading Reports. For a period of two (2) years after the date hereof, during such time as the Public Securities are listed on the Exchange, the Company shall provide, if available and upon the Representative’s request, to the Representative, at the Company’s expense, such reports published by the Exchange relating to price trading of the Public Securities, as the Representative shall reasonably request. Documents made freely available by the Exchange through its website shall be deemed to have been delivered to the Representative pursuant to this Section 3.9.3.

3.10 Payment of Expenses; General Expenses Related to the Offering. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and communication expenses relating to the registration of the Ordinary Shares to be sold in the Offering (including the Option Shares) with the Commission; (b) all Public Filing System filing fees associated with the review of the Offering by FINRA; (c) all fees and expenses relating to the listing of such Public Securities on the Exchange and such other stock exchanges as the Company and the Representative together determine; (d) all fees, expenses and disbursements relating to the registration or qualification of the Public Securities under the “blue sky” securities laws of such states and other jurisdictions as the Company and the Representative together determine (including, without limitation, all filing and registration fees); (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Public Securities under the securities laws of such foreign jurisdictions as the Company and the Representative together determine; (f) the costs of all mailing and printing of the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers’ Agreement, Underwriters’ Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Company and the Representative together determine; (g) the costs and expenses of a public relations firm as the Company and the Representative together determine; (h) the costs for conducting directors and officers background check investigations; (i) the costs of preparing, printing and delivering certificates representing the Public Securities; (j) fees and expenses of the transfer agent for the Ordinary Shares; (k) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters; (l) the costs associated with commemorative mementos and lucite tombstones, which the Company or its designee shall provide within a reasonable time after the Closing Date in such quantities as the Representative may reasonably request; (m) the fees and expenses of the Company’s accountants; (n) the fees and expenses of the Company’s legal counsel and other agents and representatives; (o) fees and expenses of the Underwriters’ Counsel (not to exceed $100,000); and (p) such Underwriters’ accountable “road show” expenses, and background check investigation expenses. The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters. In consideration of the services to be provided for hereunder, the Company shall pay to the Underwriters or their respective designees their pro rata portion (based on the Securities purchased) of an underwriting discount equal to seven percent (7.00%) of the aggregate gross proceeds raised in the Offering.

3.11 Accountable Expenses. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10 and Section 3.12, on the Closing Date, it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, an accountable expense allowance equal to $100,000, of which $50,000  has previously been paid.

3.12 Non-accountable Expenses. The Company further agrees that, in addition to the expenses payable pursuant to Sections 3.10 and 3.11, on the Closing Date, it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of the Firm Shares.

3.13 Right of First Refusal. The Company hereby grants the Representative the right of first refusal for a period of one (1) year after the closing of this Offering to act as sole investment banker, sole book-runner and/or sole placement agent, at the Representative’s sole discretion, for any and all future private and public equity, or debt offerings, including all equity linked financings (each a “Subject Transaction”), undertaken by the Company or any successor to or current or future subsidiary of the Company. The Representative shall have the sole right to determine whether any other broker dealer shall have the right to participate in a Subject Transaction and the economic terms of such participation. The Company shall not retain, engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a Subject Transaction without the prior written consent of the Representative.

3.14 Application of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application thereof described under the caption “Use of Proceeds” in the Registration Statement, the Pricing Disclosure Package, and the Prospectus.

3.15 Delivery of Earnings Statements to Security Holders. The Company shall make generally available to its security holders as soon as practicable, but not later than the first day of the fifteenth (15th) full calendar month following the date of this Agreement, an earnings statement (which need not be certified by an independent registered public accounting firm unless required by the Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.

3.16 Stabilization. Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Public Securities.

3.17 Internal Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

3.18 Accountants. As of the date of this Agreement, the Company has retained an independent registered public accounting firm reasonably acceptable to the Representative, and the Company shall continue to retain a nationally recognized independent registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable to the Representative.

3.19 FINRA. For a period of sixty (60) days from the later of the Closing Date or the Option Closing Date, except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company’s securities or (iii) any beneficial owner of the Company’s unregistered equity securities which were acquired during the 180 days immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

3.20 No Fiduciary Duties. The Company acknowledges and agrees that the Underwriters’ responsibility to the Company is solely contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement, except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

3.21 Company Lock-Up Agreements. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of one year after the date of this Agreement (the “Lock-Up Period”), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company, other than a registration statement on Form S-4 or Form S-8; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit or similar financing agreements; or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise. The restrictions contained in this Section shall not apply to (i) the Ordinary Shares to be sold hereunder, (ii) the issuance by the Company of Ordinary Shares upon the exercise of a stock option or warrant or the conversion of a security outstanding on the date hereof, or other issuances of additional shares in accordance with the terms of securities, in each case, as disclosed in the Registration Statement, Disclosure Package and Prospectus, provided that such options, warrants, and securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, or (iii) the issuance by the Company of stock options or shares of capital stock of the Company under any equity compensation plan of the Company, provided that in each of (ii) and (iii) above, the underlying shares shall be restricted from sale during the entire Lock-Up Period.

3.22 Release of D&O Lock-Up Period. If the Representative, in its sole discretion, agrees to release or waive the restrictions set forth in the Lock-Up Agreements described in Section 2.24 hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.

3.23 Blue Sky Qualifications. The Company shall use its reasonable best efforts, in cooperation with the Underwriters, if necessary, to qualify the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Company and the Representative together determine and to maintain such qualifications in effect so long as required to complete the distribution of the Public Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.

3.24 Reporting Requirements. The Company, during the period when a prospectus relating to the Public (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities as may be required under Rule 463 under the Securities Act Regulations.

4.  Conditions of Underwriters’ Obligations. The obligations of the Underwriters to purchase and pay for the Public Securities, as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:

4.1 Regulatory Matters.

4.1.1 Effectiveness of Registration Statement; Rule 430A Information. The Registration Statement has become effective not later than 5:30 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.

4.1.2 FINRA Clearance. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.

4.1.3 Exchange Stock Market Clearance. On the Closing Date, the Company’s Ordinary Shares, including the Firm Shares, shall have been approved for listing on the Exchange, subject only to official notice of issuance. On the first Option Closing Date (if any), the Company’s Ordinary Shares, including the Option Shares, shall have been approved for listing on the Exchange, subject only to official notice of issuance.

4.1.4 Escrow Agreement. On the Closing Date, the Company shall have entered into the Escrow Agreement with the Representative and the Escrow Agent, and such agreement shall be in full force and effect.

4.2 Company Counsel Matters.

4.2.1 Closing Date Opinion of Counsel. On the Closing Date, the Representative shall have received the written opinion and negative assurance letter of Loeb & Loeb LLP., counsel to the Company, dated the Closing Date and addressed to the Representative, in form and substance reasonably satisfactory to the Representative.

4.2.2 Option Closing Date Opinion of Counsel. On the Option Closing Date, if any, the Representative shall have received the written opinions and negative assurance letters of the counsel listed in Section 4.2.1 dated the Option Closing Date, addressed to the Representative and in form and substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made by such counsel in their opinion delivered on the Closing Date.

4.2.3 Reliance. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements or certificates shall be delivered to Underwriters’ Counsel if requested.

4.3 Comfort Letters.

4.3.1 Cold Comfort Letter. At the time this Agreement is executed you shall have received a cold comfort letter from the Auditor containing statements and information of the type customarily included in accountants’ comfort letters with respect to the financial statements and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.

4.3.2 Bring-down Comfort Letter. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date not more than three (3) Business Days prior to the Closing Date or the Option Closing Date, as applicable.

4.4 Officers’ Certificates.

4.4.1 Officers’ Certificate. The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer and its Chief Financial Officer stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference in the Pricing Disclosure Package, any Material Adverse Change in the financial position or results of operations of the Company, or any change or development that, singularly or in the aggregate, would involve a Material Adverse Change or a prospective Material Adverse Change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except as set forth in the Prospectus.

4.4.2 Secretary’s Certificate. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Closing Date, as the case may be, respectively, certifying: (i) that the Governing Documents are true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Company’s Board of Directors (and any pricing committee thereof) relating to the Offering are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.

4.5 No Material Changes. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been no Material Adverse Change or development involving a prospective Material Adverse Change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before or by any court or Federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may result in a Material Adverse Change, except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

4.6 Delivery of Agreements.

4.6.1 Lock-Up Agreements. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the Lock-Up Agreements from each of the persons listed in Schedule 3 hereto that the Company was able to obtain using its best efforts.

4.6.2 Escrow Agreement. On or before the date of this Agreement, the Company and the Representative shall have entered into the Escrow Agreement, in a form satisfactory to the Representative, with the Escrow Agent.

4.7 Additional Documents. At the Closing Date and at each Option Closing Date (if any) Underwriters’ Counsel shall have been furnished with such documents and opinions as they may reasonably require for the purpose of enabling Underwriters’ Counsel to deliver an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representative and Underwriters’ Counsel.

5. Indemnification.

5.1 Indemnification of the Underwriters.

5.1.1 General. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates, counsel, and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the “Underwriter Indemnified Parties,” and each an “Underwriter Indemnified Party”), against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a “Claim”), (i) arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement, the Pricing Disclosure Package, any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters Communication (as from time to time each may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including any “road show” or investor presentations made to investors by the Company (whether in person or electronically); or (C) any application or other document or written communication (in this Section 5, collectively called “application”) executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, the Underwriters’ Information or (ii) otherwise arising in connection with or allegedly in connection with the Offering. The Company also agrees that it will reimburse each Underwriter Indemnified Party for all fees and expenses (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) (collectively, the “Expenses”), and further agrees wherever and whenever possible to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending any Claim.

5.1.2 Procedure. If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval of such Underwriter Indemnified Party) and payment of actual expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the Company and shall be advanced by the Company. The Company shall not be liable for any settlement of any action effected without its consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Underwriters, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified Party, from all liabilities, expenses and claims arising out of such action for which indemnification or contribution may be sought and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any Underwriter Indemnified Party.

5.2 Indemnification of the Company. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, the Underwriters’ Information. In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.

5.3 Contribution.

5.3.1 Contribution Rights. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other, from the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement (before deducting expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total underwriting discounts and commissions received by the Underwriters with respect to the Ordinary Shares purchased under this Agreement, as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not consider the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Offering of the Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

5.3.2 Contribution Procedure. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party (“contributing party”), notify the contributing party of the commencement thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement thereof within the aforesaid fifteen (15) days, the contributing party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available. Each Underwriter’s obligations to contribute pursuant to this Section 5.3.2 are several and not joint.

6. Default by an Underwriter.

6.1 Default Not Exceeding 10% of Firm Shares or Option Shares. If any Underwriter or Underwriters shall default in its or their obligations to purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised hereunder, and if the number of the Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate ten percent (10%) of the number of Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.

6.2 Default Exceeding 10% of Firm Shares or Option Shares. In the event that the default addressed in Section 6.1 relates to more than ten percent (10%) of the Firm Shares or Option Shares, the Representative may in its discretion arrange for itself or for another party or parties to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one (1) Business Day after such default relating to more than ten percent (10%) of the Firm Shares or Option Shares, the Representative does not arrange for the purchase of such Firm Shares or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure another party or parties satisfactory to the Representative to purchase said Firm Shares or Option Shares on such terms. In the event that neither the Representative nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this Section 6, this Agreement will automatically be terminated by you or the Company without liability on the part of the Company (except as provided in Sections 3.10 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided, further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.

6.3 Postponement of Closing Date. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of Underwriters’ Counsel may thereby be made necessary. The term “Underwriter” as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been a party to this Agreement with respect to such Ordinary Shares.

7. Additional Covenants.

7.1 Board Composition and Board Designations. The Company shall ensure as of the Closing Date and the Option Closing Date, if any, that: (i) the qualifications of the persons serving as members of the Board of Directors and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have its Public Securities listed on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one (1) member of the Audit Committee of the Board of Directors qualifies as an “audit committee financial expert,” as such term is defined under Regulation S-K and the listing rules of the Exchange.

7.2 Prohibition on Press Releases and Public Announcements. The Company shall not issue press releases or engage in any other publicity, without the Representative’s prior written consent, for a period commencing on the date hereof and ending at 5:00 p.m., Eastern time, on the first (1st) Business Day following the forty-fifth (45th) day after the Closing Date, other than normal and customary releases issued in the ordinary course of the Company’s business.

7.3 Covenant of the Underwriters. The Underwriters covenant with the Company not to take any action that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriters that otherwise would not be required to be filed by the Company thereunder but for the action of the Underwriters.

8. Effective Date of this Agreement and Termination Thereof.

8.1 Effective Date. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered counterparts of such signatures to the other party.

8.2 Termination. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared by a New York State or Federal authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Shares or Option Shares; or (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representative shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material change in general market conditions as in the Representative’s judgment would make it impracticable to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriters for the sale of the Public Securities.

8.3 Expenses. Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section 6.2 above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable (including the fees and disbursements of Underwriters’ Counsel) up to an aggregate maximum of $200,000 (with a credit for fees initially disbursed to the Representative by the Company); provided, however, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).

8.4 Indemnification. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 6 shall remain in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.

8.5 Representations, Warranties, Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Public Securities.

9. Miscellaneous.

9.1 Notices. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return receipt requested), personally delivered or sent by electronic transmission and confirmed and shall be deemed given when so delivered or emailed and confirmed (which may be by email) or if mailed, two (2) days after such mailing.

If to the Representative:

Cathay Securities, Inc.

40 Wall Street, Suite 3600

New York, NY 10005

with a copy (which shall not constitute notice) to:

Haneberg Hurlbert PLC

1111 East Main Street, Suite 2010

Richmond, Virginia 23219

Attn: Bradley A. Haneberg, Esq.

Email: brad@hbhblaw.com

If to the Company:

Star Fashion Culture Holdings Limited

12F, No.611, Sishui Road

Huli District, Xiamen

People’s Republic of China

Attn: Liu Xiaohua, Chief Executive Officer

with a copy (which shall not constitute notice) to:

Loeb & Loeb LLP

2206-19 Jardine House
1 Connaught Place

Central, Hong Kong

Lawrence Venick, Esq.

Email: lvenick@loeb.com

9.2 Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

9.3 Amendment. This Agreement may only be amended by a written instrument executed by each of the parties hereto.

9.4 Entire Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that certain engagement letter between the Company and WestPark Capital, Inc. dated September 28, 2023, as amended and assigned to Cathay Securities, Inc. shall remain in full force and effect.

9.5 Binding Effect. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term “successors and assigns” shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.

9.6 Governing Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

9.7 Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.

9.8 Waiver, etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Agreement or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non- compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non- compliance or non-fulfillment.

If the foregoing correctly sets forth the understanding between the Company and the Representative, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

SCHEDULE 1

Underwriters

SCHEDULE 2-A

Pricing Information

Number of Firm Shares: 2,150,000

Number of Option Shares: 322,500

Public Offering Price per Share: $4.00

Underwriting Discount per Share: $0.28

Proceeds to Company per Share (before expenses): $3.72

SCHEDULE 2-B

Issuer General Use Free Writing Prospectuses

Free writing prospectus dated August 23, 2024

Filed pursuant to Rule 433 of the Securities Act of 1993, as amended

Relating to Preliminary Prospectus dated August 13, 2024

Registration No. 333-280198

SCHEDULE 2-C

Written Testing-the-Waters Communications

N/A

SCHEDULE 3

List of Lock-Up Parties

Liu Xiaohua

Zhang Pingting

Xingji ZhangPingting Limited

Wei Meizhong

You Zhi

Gut Leut Ming

Zhan Jie

Xingji ZhanJie Limited

Fu Yao

Intersteller F.Y Limited

Wen Hao Xiang

EXHIBIT A

Lock-Up Agreement

________, 2024

Cathay Securities, Inc.

40 Wall Street, Suite 3600

New York, NY 10005

As Representative of the several Underwriters

named on Schedule 1 to the Underwriting Agreement

Ladies and Gentlemen:

The undersigned understands that Cathay Securities, Inc. (the “Underwriter”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Star Fashion Culture Holdings Limited, a Cayman Islands company (the “Company”), providing for the initial public offering (the “Public Offering”) of Class A ordinary shares, par value US$0.00001 per share, of the Company (the “Shares”).

To induce the Underwriter to continue their efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Underwriter, the undersigned will not, during the period commencing on the date hereof and ending on ______ (180 days after the date of the final prospectus (the “Prospectus”) relating to the Public Offering (the “Lock-Up Period”)), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company, now owned by the undersigned or any affiliate of the undersigned or with respect to which the undersigned or any affiliate of the undersigned has acquired the power of disposition; the shares of common stock owned by the undersigned are hereinafter referred to as the “Lock-Up Securities”); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Lock-Up Securities, whether any such transaction is to be settled by delivery of shares of Lock-Up Securities, in cash or otherwise; (3) except as otherwise permissible under the Underwriting Agreement, make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities.

Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Underwriter in connection with:

No provision in this lock-up agreement shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable or exchangeable for or convertible into Shares, as applicable; provided that the undersigned does not transfer the Shares acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant to the terms of this lock-up agreement.

The undersigned understands that the Company and the Underwriter are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representative, successors and assigns.

The undersigned understands that, if the Underwriting Agreement is not executed by ___________, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares to be sold thereunder, then this lock-up agreement shall be void and of no further force or effect.

Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriter.

This lock-up agreement may not be amended or otherwise modified in any respect without the written consent of each of the Company, the Underwriter and the undersigned. This lock-up agreement shall be construed and enforced in accordance with the laws of the State of California without regard to the principles of conflict of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern District of California and the courts of the State of California located in Los Angeles, for the purposes of any suit, action or proceeding arising out of or relating to this lock-up agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the Company at the address in effect for notices to it under the Underwriting Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands that this lock-up agreement does not intend to create any relationship between the undersigned and the Underwriter.

By signing below, the Company agrees to enforce the restrictions on transfer set forth in this lock-up agreement.

EXHIBIT B

Form of Press Release

STAR FASHION CULTURE HOLDINGS LIMITED

[Date]

Star Fashion Culture Holdings Limited (the “Company”) announced today that Cathay Securities, Inc., acting as representative for the underwriters in the Company’s recent public offering of 2,260,000 of the Company’s Class A ordinary shares, $0.00001 par value per share, is [waiving] [releasing] a lock-up restriction with respect to _______ of the Company’s Class A ordinary shares held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on , 20___ and the shares may be sold on or after such date.

This press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.